TipRanks
Fate Therapeutics (FATE)
NASDAQ:FATE
US Market
Want to see FATE full AI Analyst Report?

Fate Therapeutics (FATE) Drug Pipeline

1,293 Followers
Drug Name
Condition
Stage
Status
Study Name
Trial Start Date
Article
Ft839
Systemic Lupus Erythematosus (Sle), Rheumatoid Arthritis (Ra), Systemic Sclerosis (Ssc), Anca-Associated Vasculitis (Aav), Idiopathic Inflammatory Myositis (Iim)
Phase I/II
Recruiting
FT839 in Autoimmune Diseases
Aug 24, 2026
―
Ft819
Systemic Lupus Erythematosus, Lupus Nephritis, Lupus Nephritis - Who Class Iii, Lupus Nephritis - Who Class Iv, Sle - Systemic Lupus Erythematosus
Phase II
Recruiting
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
Apr 30, 2026
―
Trastuzumab, Paclitaxel, Cetuximab, Ft836
Ovarian Cancer, Colorectal Cancer, Non-small Cell Lung Cancer, Breast Cancer, Head And Neck Squamous Cell Carcinoma, Endometrial Carcinoma
Phase I
Recruiting
FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors
Oct 08, 2025
Bendamustine, Cyclophosphamide, Fludarabine, Ft819
Systemic Lupus Erythematosus (Sle), Systemic Sclerosis (Ssc), Antineutrophilic Cytoplasmic Antibody (Anca)- Associated Vasculitis (Aav), Idiopathic Inflammatory Myositis (Iim)
Phase I
Recruiting
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Mar 06, 2024
Bendamustine, Docetaxel, Cyclophosphamide, Fludarabine, Cisplatin, Cetuximab, Ft825
Advanced Solid Tumor
Phase I
Recruiting
FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors
Jan 27, 2024
Rituximab, Bendamustine, Cyclophosphamide, Fludarabine, Ft522
Relapsed/Refractory B-Cell Lymphoma
Phase I
Completed
FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)
Jul 10, 2023
―
Cyclophosphamide, Fludarabine, Bendamustine, Il-2, Ft819, Interleukin-2
Chronic Lymphocytic Leukemia, Lymphoma, B-Cell, Precursor B-Cell Acute Lymphoblastic Leukemia
Phase I
Active Not Recruiting
FT819 in Subjects With B-cell Malignancies
Nov 10, 2020
―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases:
a. Preclinical testing
b. Phase 1 – Safety and dosage
c. Phase 2 – Effectiveness and side effects
d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments
e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
    What is a clinical trial?
    A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
      What drugs does Fate Therapeutics (FATE) have in its pipeline
      FATE is currently developing the following drugs: Ft839, Ft819, Trastuzumab, Paclitaxel, Cetuximab, Ft836. These drug candidates are in various stages of clinical development as the company works toward FDA approval.